. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:17.645959"^^ . . . "for COVID-19 therapy" . "(388, 399)" . "considered" . "498" . "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone" . "(388, 399)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-2" . "chloroquine" . "therapy" . "RSA" . "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" . "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" . . .